Allergic rhinitis affects 1 in 5 people in the US and is associated with high economic burden. Allergic rhinitis (AR) can lead to decreased energy, poor concentration, disturbed sleep, and decrements in performance at school and work.
In 2011, US costs of AR were $14 billion, with 60% towards prescription medications. Additional dollars were spent to treat conditions for which AR is a predisposing factor such as asthma, sinusitis.
Subcutaneous immunotherapy just commemorated its centennial anniversary. It is indicated to treat AR in patients with symptoms not adequately controlled by medications, avoidance measures, or those experiencing adverse effects of medications, or who wish to reduce long term use of medication.
Patients with newly diagnosed AR initiating immunotherapy incur significantly lower health care costs than matched control subjects beginning 3 months after immunotherapy initiations and continuing throughout the 18-month follow-up period.
You Might Also Enjoy...
Two large trials, DREAM and MENSA have found IL-5 therapy with mepolizumab to lower risk of exacerbation in patients with asthma with an eosinophilic phenotype.
Mold allergy is difficult to diagnose due to lack of standardized test material.
The current standard for diagnosis of Eosinophilic Esophagitis (EoE) is endoscopy with esophageal biopsy to determine the eosinophil count
Skin prick testing and serum IgE measurement are limited in their ability to predict positive or negative responses to oral peanut challenge.
Bronchial Thermoplasty (BT) has been shown to result in significant improvements in a number of asthma control measures in three randomized clinical trials in patients with moderate-to-severe, persistent asthma.
Recent studies have suggested that early regular exposure to allergenic foods may reduce the risk of food allergy.
